Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.67 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.51 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CASP3 | P42574 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL608621 | 0.93 | KMT2A (0.73) | KMT2AEPHX2FABP7FABP5CA1 | |
| SCHEMBL14639568 | 0.91 | KMT2A (0.81) | KMT2AEPHX2FABP7FABP5CA1 | |
| SCHEMBL14086099 | 0.91 | KMT2A (0.81) | KMT2AEPHX2FABP7FABP5CA1 | |
| SCHEMBL29397906 | 0.87 | KMT2A (0.81) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL178687 | 0.87 | KMT2A (0.81) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29423575 | 0.87 | KMT2A (0.81) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL29904323 | 0.86 | KMT2A (0.64) | KMT2AEPHX2FABP7FABP5CA1 | |
| SCHEMBL4741668 | 0.86 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL5582202 | 0.86 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 | |
| SCHEMBL30275540 | 0.86 | KMT2A (0.67) | KMT2AEPHX2FABP7FABP5CASP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100267941-A1 | IRNA AGENTS WITH BIOCLEAVABLE TETHERS | ALNYLAM PHARMACEUTICALS, INC. (US) | 2010-10-21 | — | — | US | disclosed |
| US-7723509-B2 | Conjugated lipophilic group with a modified nucleotide is used to target disease gene, cells, tissue, for drug delivery to target tumor cells; ribose sugar of nucleotide is replaced with a cyclic carrier which has at least one attached phosphate or phosphorothioate group; biodrugs | ALNYLAM PHARMACEUTICALS (US) | 2010-05-25 | — | — | US | disclosed |
| EP-1347784-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | Bristol-Myers Squibb Pharma Company (US) | 2003-10-01 | — | — | EP | disclosed |
| WO-2002036173-A2 | SIMULTANEOUS DUAL ISOTOPE IMAGING OF CARDIAC PERFUSION AND CARDIAC INFLAMMATION | BRISTOL-MYERS SQUIBB PHARMA COMPANY (US) | 2002-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100267941-A1 | IRNA AGENTS WITH BIOCLEAVABLE TETHERS | DCLRE1A, PARP1, LIG1 | KMT2A 2087/4885EPHX2 3535/4885FABP7 2425/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.